129 related articles for article (PubMed ID: 37052937)
1. Wang D, Sun Z, Zhu X, et al. GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT. Blood. 2022;140(26):2788-2804.
Blood; 2023 Apr; 141(15):1896. PubMed ID: 37052937
[No Abstract] [Full Text] [Related]
2. GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT.
Wang D; Sun Z; Zhu X; Zheng X; Zhou Y; Lu Y; Yan P; Wang H; Liu H; Jin J; Zhu H; Sun R; Wang Y; Fu B; Tian Z; Wei H
Blood; 2022 Dec; 140(26):2788-2804. PubMed ID: 35981475
[TBL] [Abstract][Full Text] [Related]
3. Restoring NK cell functions in AML relapse.
Kim S; Choi J
Blood; 2022 Dec; 140(26):2765-2766. PubMed ID: 36580344
[No Abstract] [Full Text] [Related]
4. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Hattori N; Nakamaki T
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Safety of NK Cell in the Prevention of Leukemia Relapse Post-transplantation and in Treatment of the Elderly Leukemia Patients].
Liu J; Zheng XL; Xue M; Zhu L; Ding L; Han DM; Yan HM; Li S; Ma JD; Tan XT; Zhou JX; Guo ZK; Wang HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1267-1271. PubMed ID: 35981396
[TBL] [Abstract][Full Text] [Related]
6. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?
Yoon JH; Kim HJ; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Biol Blood Marrow Transplant; 2014 Jan; 20(1):80-8. PubMed ID: 24149098
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia].
Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution.
Lin CH; Chen TC; Shih YH; Chou CW; Hsu CY; Li PH; Teng CJ
J Int Med Res; 2022 Feb; 50(2):3000605221078466. PubMed ID: 35187981
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
11. Higher Dose of CD34
Zhao F; Shi Y; Chen X; Zhang R; Pang A; Zhai W; Yang D; He Y; Feng S; Zhang P; Jiang E; Han M
Transplant Cell Ther; 2022 Sep; 28(9):589.e1-589.e10. PubMed ID: 35714907
[TBL] [Abstract][Full Text] [Related]
12. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia.
Ge L; Ye F; Mao X; Chen J; Sun A; Zhu X; Qiu H; Jin Z; Miao M; Fu C; Ma X; Chen F; Xue S; Ruan C; Wu D; Tang X
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1040-7. PubMed ID: 24704575
[TBL] [Abstract][Full Text] [Related]
13. How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML.
Gutman JA
Best Pract Res Clin Haematol; 2022 Dec; 35(4):101411. PubMed ID: 36517129
[TBL] [Abstract][Full Text] [Related]
14. Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia.
Silla L; Dulley F; Saboya R; Kerbauy F; de Moraes Arantes A; Pezzi A; Gross LG; Paton E; Hamerschlak N
Eur J Haematol; 2017 Feb; 98(2):177-183. PubMed ID: 27621140
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes.
Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Watanabe K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Leuk Lymphoma; 2016; 57(1):76-80. PubMed ID: 26084204
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.
Muto T; Takeuchi M; Yamazaki A; Sugita Y; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Aotsuka N; Iseki T; Nakaseko C
Int J Hematol; 2015 Jul; 102(1):86-92. PubMed ID: 25758097
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
18. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.
Aoki J; Ishiyama K; Taniguchi S; Fukuda T; Ohashi K; Ogawa H; Kanamori H; Eto T; Iwato K; Sakamaki H; Morishima Y; Nagamura T; Atsuta Y; Takami A
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2029-33. PubMed ID: 25196856
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of risk factors of relapse after allogeneic hematopoietic stem cell transplantation in patients with t (8;21) acute myeloid leukemia].
Guo WW; Liu X; Pang AM; Zhai WH; Yang DL; Chen X; Ma QL; He Y; Zhang RL; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):998-1004. PubMed ID: 35045670
[No Abstract] [Full Text] [Related]
20. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]